Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase I clinical study of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of freshly isolated autologous adipose tissue-derived stromal/stem (regenerative) cell.

Regenerative therapy·2018

Same author

Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.

Expert opinion on drug safety·2018

Same author

Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis.

Japanese journal of clinical oncology·2018

Same author

Significant Association Between Coronary Artery Low-Attenuation Plaque Volume and Apnea-Hypopnea Index, But Not Muscle Sympathetic Nerve Activity, in Patients With Obstructive Sleep Apnea Syndrome.

Circulation journal : official journal of the Japanese Circulation Society·2018

Same author

A case of chronic pancreatitis exacerbation associated with pancreatic arteriovenous malformation: a case report and literature review.

Clinical journal of gastroenterology·2018

Same author

The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication.

Scientific reports·2018

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

[Dendritic cell-based immunotherapy for hepatocellular carcinoma].

Yasunari Nakamoto¹, Shuichi Kaneko

¹Dept. of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|March 25, 2010

Summary

Dendritic cell (DC) immunotherapy after transcatheter hepatic arterial embolization (TAE) shows promise for reducing hepatocellular carcinoma (HCC) recurrence. OK-432-stimulated DCs prolonged recurrence-free survival in HCC patients, suggesting a beneficial antitumor immune response.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Related Experiment Videos

Last Updated: Jun 14, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Area of Science:

Immunotherapy
Oncology
Hepatology

Context:

Hepatocellular carcinoma (HCC) presents a significant challenge due to high recurrence rates post-curative treatments.
Transcatheter hepatic arterial embolization (TAE) is a common treatment modality for HCC.
Dendritic cell (DC)-based immunotherapy offers a potential strategy to overcome treatment limitations and prevent tumor recurrence.

Purpose:

To evaluate the bioactivity and therapeutic effects of infusing dendritic cells (DCs) into HCC tissues following TAE.
To assess the safety and efficacy of administering monocyte-derived DCs during TAE procedures in HCC patients.
To compare outcomes between patients receiving DC immunotherapy plus TAE and historical controls treated with TAE alone.

Summary:

Monocyte-derived DCs were prepared and stimulated with either peptides or OK-432 before intra-arterial administration during TAE in HCC patients.
Peptide-stimulated DCs were phenotypically immature, while OK-432-stimulated DCs exhibited high expression of the activation marker CD83.
No significant adverse events were observed beyond those associated with TAE, indicating a favorable safety profile.
Survival analysis revealed that patients treated with OK-432-stimulated DCs demonstrated prolonged recurrence-free survival compared to historical controls.

Impact:

OK-432-stimulated DC transfer following TAE induces beneficial anti-tumor immune responses in HCC patients.
This immunotherapy strategy shows potential for prolonging recurrence-free survival and reducing tumor recurrence rates in hepatocellular carcinoma.
DC-based immunotherapy represents a promising novel approach for managing HCC and improving patient outcomes.